You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華檢醫療(01931.HK)預計上半年純利同比增逾100%
格隆匯 07-13 20:51

格隆匯7月13日丨華檢醫療(01931.HK)公佈,預期集團相較於截至2020年6月30日止六個月,於截至2021年6月31日止6個月將錄得(i)收益增加約20%;(ii)集團母公司擁有人應占溢利大幅增加逾100%;及(iii)集團母公司擁有人應占經調整溢利大幅增加逾40%。

報吿期間,收益、集團母公司擁有人應占溢利及集團母公司擁有人應占經調整溢利的增加主要是由於(i)終端客户對體外診斷("IVD")產品的需求恢復,這是由於新型冠狀病毒病的影響減小,令到醫院的營運回復正常,給集團IVD產品分銷業務的盈利能力帶來正面影響;及(ii)毛利率增加所致。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account